While Trevi Therapeutics Inc has underperformed by -2.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TRVI rose by 95.75%, with highs and lows ranging from $9.92 to $2.36, whereas the simple moving average jumped by 40.87% in the last 200 days.
On August 21, 2025, Morgan Stanley started tracking Trevi Therapeutics Inc (NASDAQ: TRVI) recommending Overweight. A report published by Cantor Fitzgerald on July 01, 2025, Initiated its previous ‘Overweight’ rating for TRVI. H.C. Wainwright also rated TRVI shares as ‘Buy’, setting a target price of $21 on the company’s shares in an initiating report dated May 28, 2025. Raymond James March 10, 2025d the rating to Strong Buy on March 10, 2025, and set its price target from $9 to $29. Needham resumed its ‘Buy’ rating for TRVI, as published in its report on March 10, 2025. H.C. Wainwright’s report from December 12, 2024 suggests a price prediction of $7.50 for TRVI shares, giving the stock a ‘Buy’ rating. Leerink Partners also rated the stock as ‘Outperform’.
Analysis of Trevi Therapeutics Inc (TRVI)
One of the most important indicators of Trevi Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -35.74% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 22.42, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and TRVI is recording 2.08M average volume. On a monthly basis, the volatility of the stock is set at 7.98%, whereas on a weekly basis, it is put at 13.85%, with a gain of 6.12% over the past seven days. Furthermore, long-term investors anticipate a median target price of $19.58, showing growth from the present price of $8.06, which can serve as yet another indication of whether TRVI is worth investing in or should be passed over.
How Do You Analyze Trevi Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 33.70%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 60.31% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
